ENGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). enGene Holdings's Average Total Inventories for the three months ended in Jan. 2024 was $0.00 Mil. enGene Holdings's Cost of Goods Sold for the three months ended in Jan. 2024 was $0.00 Mil.
The historical rank and industry rank for enGene Holdings's Days Inventory or its related term are showing as below:
enGene Holdings's Days Inventory stayed the same from Jan. 2023 (0.00) to Jan. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for enGene Holdings's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings Annual Data | |||||||||
Trend | Oct20 | Oct21 | Oct22 | Oct23 | |||||
Days Inventory | - | - | - | - |
enGene Holdings Quarterly Data | ||||||||||
Oct20 | Oct21 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Days Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, enGene Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, enGene Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where enGene Holdings's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
enGene Holdings's Days Inventory for the fiscal year that ended in Oct. 2023 is calculated as
Days Inventory (A: Oct. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Oct. 2022 ) | + | Total Inventories (A: Oct. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Oct. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
enGene Holdings's Days Inventory for the quarter that ended in Jan. 2024 is calculated as:
Days Inventory (Q: Jan. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Oct. 2023 ) | + | Total Inventories (Q: Jan. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Jan. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings (NAS:ENGN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
enGene Holdings's Inventory Turnover for the three months ended in Jan. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
enGene Holdings's Inventory to Revenue for the three months ended in Jan. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of enGene Holdings's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard M Glickman | director | C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Jason David Hanson | director, officer: Chief Executive Officer | 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463 |
Lumira Capital Investment Management Inc. | 10 percent owner | 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
Richard Paul Bryce | officer: Chief Medical Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Fonds De Solidarite Des Travailleurs Du Quebec | 10 percent owner | 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4 |
Gerald A Brunk | director | C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142 |
Jasper Bos | director | BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102 |
Grassin Alexandre Jean-rene Erwan | officer: Int. Chief Financial Officer | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
Anthony Tzeyew Cheung | officer: Chief Technology Officer | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
Alexander Julian Nichols | officer: Pres. & Chief Operating Ofc. | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
James Crowley Sullivan | officer: Chief Scientific Officer | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
Forbion Growth Sponsor Feac I B.v. | 10 percent owner | GOOIMEER 2 35,, NAARDEN P7 1411DC |
Forbion Growth Opportunities Fund I Cooperatief U.a. | 10 percent owner | GOOIMEER 235, 1411 DC, NAARDEN P7 00000 |
Forbion Growth Management B.v. | 10 percent owner | C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807 |
From GuruFocus
By PRNewswire • 12-22-2023
By PRNewswire • 12-19-2023
By PRNewswire • 11-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.